Merrimack Pharmaceuticals, Inc.
) recently announced that it has completed the enrollment process
for a phase II trial on its oncology candidate, MM-121. The phase
II trial is designed to evaluate the efficacy of MM-121 in
) Taxol (paclitaxel) in advanced ovarian cancer patients who are
platinum-resistant or platinum refractory. Merrimack is
) for MM-121.
BRISTOL-MYERS (BMY): Free Stock Analysis
MERRIMACK PHAR (MACK): Free Stock Analysis
NOVO-NORDISK AS (NVO): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
To read this article on Zacks.com click here.
The open-label, randomized phase II trial is designed to evaluate
the efficacy of MM-121 in combination with Taxol versus Taxol
alone in 223 patients enrolled in the US and Europe. The primary
endpoint of the trial is progression-free survival (PFS).
Merrimack expects that top-line data from the phase II trial will
be released in the second half of 2013.
MM-121 is also being evaluated for other oncology indications
including hormone sensitive breast cancer, non-small cell lung
cancer (NSCLC) and HER2 negative neoadjuvant breast cancer.
We note that Merrimack and Sanofi inked an exclusive global
licensing agreement in Oct 2009 for the development and
co-commercialization of MM-121. Under the terms of the agreement,
for each indication, Merrimack will be responsible for the
development of MM-121 till phase II proof-of-concept. Thereafter
Sanofi will take up development and commercialization activities.
Merrimack has the right to co-promote MM-121in the US, following
Sanofi carries a Zacks Rank #3 (Hold) in the short run, while
Merrimack carries a Zacks Rank #4 (Sell). Right now,
) looks more attractive in the pharma space with a Zacks Rank #2